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Abstract
Because of evidence of causal association between antibiotic use and bacter-
ial resistance, the implementation of national policies has emerged as a interest-
ing tool for controlling and reversing bacterial resistance. The aim of this study
is to assess the impact of public policies on antibiotic use in Europe using a
di¤erences-in-di¤erences approach. Comparable data on systemic administered
antibiotics in 21 European countries are available for a 11-years panel between
1997 and 2007. Data on national campaigns are drawn from the public health
literature. We estimate an econometric model of antibiotic consumption with
country xed e¤ects and control for the main socioeconomic and epidemiologi-
cal factors. Lagged values and the instrumental variables approach are applied
to address endogeneity aspects of the prevalence of infections and the adoption
of national campaigns. We nd evidence that public campaigns signicantly
reduce the use of antimicrobials in the community by 1:4 to 3:7 dened daily
doses per 1; 000 inhabitants. This roughly represents an impact between 7:2%
and 18:5% on the mean level of antibiotic use in Europe between 1997 and 2007.
The e¤ect is robust across di¤erent measurement methods. Further research is
needed to investigate the e¤ectiveness of policy interventions targeting di¤erent
social groups such as general practitioners or patients.
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1 Introduction
The overuse of antibiotics is the main force driving the increase of bacterial resis-
tance, which represents a major threat to public health. Antimicrobials may lose
e¤ectiveness since they are frequently prescribed for viral infections (Park et al.,
2005) or can be sold without an o¢ cial medical prescription (Llor and Cots, 2009;
Vaandnen et al., 2006). Large volumes of antimicrobials are also used in agricul-
ture and veterinary medicine, and in many consumer products where benets are
often unclear (Tan et al., 2002). As illustrated in Figure 1, di¤erences across Eu-
ropean countries in antibiotic prescribing practices measured in dened daily doses
per 1,000 inhabitants (DID) partially mirror di¤erences in the levels of bacterial re-
sistance captured by the rate of penicillin-non-susceptible Streptococcus pneumoniae
isolates (PNSP).
E¤orts to reduce bacterial resistance through a control of antibiotic use include
the limitation of prescriptions, surveillance, and a more careful use of antibiotics
in agriculture and food-producing animals. More recently, public authorities have
taken an interest in encouraging appropriate consumption of antibiotics in the com-
munity (Hawkings et al., 2008; Sabuncu et al. 2009). Cost-e¤ectiveness studies
on antibiotic treatments are now developed to consider the inuence of bacterial
resistance (Sabes-Figuera et al., 2008). Because the association between antibiotic
use and bacterial resistance may cross regional borders within countries, the im-
plementation of national policies towards antibiotic consumption has emerged as
an important tool for controlling and reversing bacterial resistance. However, the
e¤ects of these policies are still unclear.
Several studies describe and review national policies towards antibiotic consump-
tion in specic countries. Goossens et al. (2006), for instance, consider policies to-
wards the e¢ cient use of antibiotics in Belgium and France. However, the literature
lacks studies providing empirical evidence on the impact of national policies across
Europe. Huttner et al. (2010) summarize the characteristics of public campaigns
in high-income countries but fail to provide su¢ cient statistical evidence on their
impact. An econometric approach is used by Masiero et al. (2010) to investigate
socioeconomic determinants of antibiotic use across Europe. The authors do not
account for the e¤ects of public policies towards the consumption of antimicrobials.
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The aim of this study is to assess the impact of public education campaigns on
antibiotic use in Europe by means of a di¤erences-in-di¤erences approach, a largely
used empirical methodology on the e¤ects of various treatments (Bertrand et al.,
2004). We draw information on national campaigns from the public health litera-
ture and use data publicly available on antibiotic consumption and socioeconomic
determinants for an 11-years period (1997-2007). We control for unobserved indi-
vidual heterogeneity by means of xed-e¤ects estimations and address endogeneity
aspects of infections and policies with lagged and instrumental variables methods.
The paper is organized as follows. In section 2 we review the literature on policies
towards the use of antibiotics and provide a brief overview of public interventions
implemented in the European countries. In section 3 we propose an econometric
model of antibiotic consumption where the impact of national campaigns is assessed
after controlling for the main determinants of consumption. Data are described in
section 4. Estimation results and discussion of main ndings are presented in section
5. Section 6 concludes.
2 Public policies toward antibiotic consumption
Antimicrobial agents represent a scarce resource since their e¤ectiveness decreases
with consumption because of bacterial resistance. Di¤erent interventions may act
as an e¤ective way to tackle the problem. These can be characterized according to
the type of intervention, the geographical area involved, the targeted agents, the
instruments used and their message.
As for the type of intervention, policies to improve the use of antibiotics can be
categorized in four classes according to the list proposed by Quick et al. (1991).
There are educational interventions which are persuasive and consider training of
prescribers by means of seminars, workshops, face to face or supervisory visits, and
assorted printed materials aimed at patients or prescribers. Managerial strategies
aim at guiding decision-making. They concentrate, for instance, on carrying drug
utilization reviews, giving cost information, following standard treatment guide-
lines to prescribe, and wrapping full courses of therapy. Regulatory interventions
legally constraint prescribers to control their decision making via instruments such
as registering drugs for marketing, licensing prescribers, and limiting prescribing
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or dispensing. Finally, economic interventions aim at providing nancial incentives
to institutions, providers and patients. The e¤ects of these strategies crucially de-
pend on the pricing structure, the price setting and the reimbursement mechanism
adopted.
Among the educational strategies that promote the appropriate use of antibi-
otics and that raise the public awareness of bacterial resistance, public campaigns
are one of the most widely used. In European countries, national or regional health
authorities are in charge of adopting these campaigns, depending on the level of
decentralization of the health care systems. Although antibiotic policies can be
implemented at national or subnational level, public campaigns are generally im-
plemented within a national strategy to abate resistance to antimicrobials (Huttner
et al., 2010). International organizations are sometimes involved. Rudholm (2002)
suggests that the problem of resistance is a global one. Consequently, optimal poli-
cies should consider the fact that antibiotic resistance can cross country borders and
travel far distances. Coast et al. (1998) argue that policies aimed at reducing antibi-
otic use within a country may not work in another country since local epidemiological
factors a¤ect the spreading mechanism of antibiotic resistance. González Ortiz and
Masiero (2013) suggest that regional policies could blunt the impact of policies in
neighbouring regions through the generation of local spillovers.
The majority of public campaigns are addressed to the general public, focusing
on parents of young children. Health-care professionals, specically primary care
physicians, are also targeted. The public is targeted by distributing informational
material to patients and by displaying posters in waiting rooms and pharmacies.
General practitioners receive educational material such as guidelines, information
sheets and booklets. Some campaigns combine di¤erent instruments such as adver-
tising on television and radio networks, newspapers and public transports, through
the internet or using billboards. The use of the internet to spread information about
the program is common to almost all campaigns.
Finally, regarding the message of the intervention, most campaigns attempt to
inform the public that antibiotics are not needed for treating viral infections. They
focus on respiratory tract infections and combine negative and positive messages.
The main message is that bacterial resistance is a major public health issue largely
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caused by the misuse of antibiotics. This encourages people to follow rigorously the
antibiotic dosage regime prescribed by the physician.
2.1 Previous studies on the impact of antibiotic policies
The literature on the impact of antibiotic policies is limited to studies using a descrip-
tive and qualitative approach. Goossens et al. (2006) analyse national campaigns
in two European countries with high antibiotic use, Belgium and France, between
1997 and 2003. To assess the impact of antibiotic policies, the authors compare
rates of antibiotic consumption between the two countries and England, where the
rates of antibiotic use are lower and persistent. Findings suggest evidence of reduced
antibiotic prescribing in both countries. However, these ndings cannot be general-
ized to countries with lower or already declining levels of antibiotic use. Moreover,
the study does not control for di¤erences between the two countries related to the
impact of infections, the characteristics of prescribers or demographic aspects over
the time period considered.
To assess the impact of antibiotic policies in Central and Eastern European coun-
tries, Cizman et al. (2004) administer a questionnaire to national representatives.
The questionnaire includes information about national antimicrobial resistance sur-
veillance, national consumption of antibiotics in the community and in hospitals, and
strategies to optimize the use of antimicrobials. The authors identify countries which
have restricted the use of some antibiotics for outpatients and inpatients and briey
describe other types of interventions implemented by these countries. Findings show
that only few countries have restricted the use of antimicrobials in ambulatory care,
as compared to the common practice of restricting the use of antibiotics in hospitals.
The authors realize that antibiotic policy interventions are lacking or only apply to
specic interventions or problems.
Using an exhaustive search strategy and structured interviews, Huttner et al.
(2010) classify and examine the characteristics and outcomes of 22 public campaigns
for a more rational use of antibiotics implemented at national or regional level in
high-income countries between 1990 and 2007. The majority of these campaigns (16)
are located in Europe. Looking at data on the consumption of outpatient antibiotics,
the authors try to evaluate the e¤ect of the campaigns. The study concludes that
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probably there is a relationship between a decline in the use of antibiotics and
the implementation of public campaigns. However, this conclusion is based on a
qualitative analysis rather than on a statistical/econometric analysis. The approach
has some shortcomings since most campaigns do not include a control population
and trends in consumption before the interventions are not considered. The analysis
cannot clarify whether antibiotic consumption would still have increased without the
campaign or if the duration of the intervention was too short to observe measurable
e¤ects.
In conclusion, evidence presented in empirical studies on the impact of antibiotic
policies is currently weak, mainly based on descriptive statistics and graphical analy-
sis. In the following section, we will use an econometric approach to provide more
convincing evidence of the association between the adoption of antibiotic policies
and antibiotic consumption rates.
3 The empirical approach
To investigate the e¤ects of national campaigns for a more rational use of antibiotics,
we estimate a model of outpatient antibiotic consumption using a panel data set for
a sample of 21 European countries over the period 1997-2007. The model serves as
a reduced form that considers both demand- and supply-side factors. In our simple
frame, individuals are assumed to follow doctorsprescriptions and to be compliant
with the antibiotic therapy. The consumption of outpatient antibiotics is assumed to
depend upon sociodemographic characteristics of the population, individualshealth
status, antibiotic price, the characteristics of health care supply and the adoption of
national campaigns to improve the use of antibiotics.
Antibiotic prescribing practices vary widely across European countries. Mean
gures of dened daily doses per 1,000 inhabitants for 21 countries collected by the
European Surveillance of Antimicrobial Consumption (ESAC) project between 1997
and 2007 show that France, Greece, and Luxembourg, among others, exhibit signif-
icantly higher values of antibiotic use than Austria, Denmark, and the Netherlands
(Figure 2).1 Some of these countries implemented policy interventions to reduce
1Data are reliable and exhibit a good degree of comparability since the ESAC network screens for
detection bias in sample and census data, bias by over-the counter sales and parallel trade, errors
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antibiotic consumption during the period considered; other countries did not adopt
any type of policy. Table 1 provides a summary of the adoption of national cam-
paigns to improve antibiotic use in Europe. We refer the reader to section 4 for
details about the construction of this table.
Since we have information on antibiotic consumption before and after a policy
instrument has been introduced, we are able to estimate the e¤ect of policy interven-
tions using a di¤erences-in-di¤erences (DD) approach (Bertrand et al., 2004). The
general idea of this approach is to compare the outcome, in our case the per capita
consumption of antibiotics, of two groups of countries before and after the intro-
duction of a campaign. One group, denoted the control, is composed of countries
that did not introduce any policy instrument to reduce antibiotic consumption. The
other group, the treatment, includes all countries that have adopted some policy
measures. Looking at di¤erences in the outcomes observed between the two groups
after the introduction of a policy, we can then estimate the impact of antibiotic pol-
icy interventions. The typical DD estimation with panel data with more than two
periods considers countries and years xed e¤ects. Therefore, our DD estimation
takes into account unobserved time-invariant variables.
Our empirical approach draws from Giavazzi and Tabellini (2005), who apply a
DD technique to a large sample of countries to investigate the impact of economic
and political liberalizations on economic performance, macroeconomic policy and
structural policies. We estimate the following model in the whole sample of treated
and control countries:
DIDit = 0 + 1POLICYit + xit + !i + t + "it, (1)
where DIDit denotes dened daily doses of antibiotic consumption per 1,000 inhab-
itants in country i at time t; POLICYit is a dummy variable which assumes a value
equal to 1 in the year of policy implementation and in the following years, and 0
otherwise. xit is a set of other covariates which includes the per capita national in-
come (Yit), the physiciansdensity (DPHit), the percentage of the population below
14 years of age, between 15 and 24, 25 and 64, 65 and 79, and over 80 (POP1it. . .
POP5it), the price level for a dened daily dose of antibiotics (Pit), and the popula-
in assigning medicinal product packages to the Anatomical Therapeutic Chemical Classication
(ATC), and errors in calculations of dened daily doses (Vander Stichele et al., 2004).
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tion health status measured by the impact of infectious diseases (INFit). !i captures
the country-level xed e¤ects, which are assumed constant over time; and t is the
year-specic xed e¤ect, which is assumed constant across countries. Finally, "it is
an unobserved error term with Z distribution.
By including both time and country xed e¤ects in Equation (1), we are able to
disentangle the impact of public campaigns per se from other determinants related
to country characteristics or time e¤ects. The main coe¢ cient of interest is 1 which
measures the e¤ect of public campaigns on antibiotic consumption. A negative and
signicant coe¢ cient would suggest that antibiotic policies were e¤ective in reducing
antibiotic consumption over the period 1997-2007.
To correctly identify the impact of antibiotic policy interventions, the economet-
ric model has to satisfy some assumptions. First, we need to exclude the presence of
unobserved variables a¤ecting antibiotic consumption that move systematically over
time in a di¤erent way between the two groups of countries. In our analysis, the
assumption sounds reasonable because all countries belong to Europe and, therefore,
the general trend in antibiotic consumption is expected to be similar. Moreover, the
possibility of unobserved heterogeneity should be negligible given that our regres-
sions include all main socioeconomic determinants of di¤erences in antibiotic use
across countries (xit).
One further assumption is that the decision to introduce a public campaign is
independent of the level of antibiotic consumption in a country, i.e. policies are
exogenous. This assumption is also plausible because the pressure to promote infor-
mation campaigns does not depend directly on antibiotic consumption. It probably
depends on the increasing levels of antibiotic resistance. We are clearly aware that
antibiotic resistance is partially caused by the consumption of antibiotics, which
may then indirectly inuence the adoption of antibiotic policies.
Potential endogeneity problems may lead to biased results in the estimation of
Equation (1). Since public campaigns may be driven by high levels of antibiotic use in
a country, we check the robustness of our initial results (Model 1) by endogenizing the
policy variable using an instrumental variable approach (Model 2). Unfortunately,
as we will discuss later, the limited number of instruments reduces the number
of observations. The population density, women employment rate, the production
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of milk and pig meat, the use of fertilizers, and the size of the country are used
as instruments for policies. These variables also indirectly measure the level of
bacterial resistance within a country. In contrast to bacterial resistance, they are
poorly correlated with antibiotic use. Consequently, we believe they can reasonably
be used as appropriate instruments for policies.
Another explanatory variable is potentially endogenous in our model: the pop-
ulation health status which is captured by mortality for infectious diseases. Infec-
tions are potentially endogenous since a low level of antibiotic use may favour poorer
health conditions in the population, e.g. an increased spreading of severe infections.
To tackle this problem, we estimate our models using the lagged mortality rate
for infectious diseases (INFit instead of INFit 1). This is a simple instrumental
variable approach, though pretty e¢ cacious.
One last issue is that the DD estimation results can be a¤ected by positive
serial correlation (see Bertrand et al., 2004). To cope with this problem, we report
standards errors clustered by country.
4 Data
The consumption rate of antibiotics is available for 21 European countries between
1997 and 2007. This is collected by the European Surveillance of Antimicrobial
Consumption (ESAC) project. The consumption rate is most commonly expressed
as the number of dened daily doses (DDD) per 1,000 inhabitants per day (DID).
The DDD is a technical unit based on the assumed average maintenance dose per
day for a drug used for its main indication in adults. Antibiotic use is standardized
using the ATC=DDD index for international drug consumption studies (WHO,
2011).
Annual data available on the determinants of outpatient antibiotic use are sum-
marised in Table 1. These include socioeconomic characteristics of the population
(income and demographic structure), supply-side factors (density of doctors), price
of antibiotics, and the incidence of bacterial infections measured by the rate of mor-
tality.2 We use the mortality rate for infectious diseases as a proxy for the incidence
2 Information on mortality for infectious diseases and price of pharmaceuticals are not available
for all countries or years. This reduces the total number of observations in our nal regressions.
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of infections since morbidity indicators are less complete and reliable.
Data are obtained from a variety of sources. Information on the per capita income
(measured in US dollars in purchasing power parity), the density of physicians, and
the incidence of infections are extracted from publications by the OECD (2010). The
demographic structure of the population is derived from Eurostat tables (Eurostat,
2010).
We derive price levels for antibiotics by combining information from two indica-
tors: the comparative price level index (PLI) and the harmonized annual average
price index (HICP) for pharmaceutical products. The PLI indicates the price level
of each country compared to the average price level of the 25 EU countries in 2005.
The HICP includes information on price trends for pharmaceuticals for each coun-
try during 2000 and 2005, where 2005=100. These indices are provided by Eurostat
(2010).
As for public campaigns, data collection is cumbersome and may result in incom-
plete data. Moreover, little information is available in scientic journals. For our
purpose, we draw the information on campaign characteristics from the recent re-
view by Huttner et al. (2010). The authors identify public campaigns implemented
at national level in high income countries between 1990 and 2007. Using informa-
tion from this study, we generate a dummy variable (POLICY1) which takes a value
equal to 1 in the year of implementation of the campaign, and 0 in the pre-campaign
and post-campaign years (see Table 2). Alternatively, we consider a di¤erent pol-
icy indicator (POLICY2). This is a dummy variable which takes the value 1 in the
years of campaign adoption and in the years post-campaign, and 0 in years before the
campaign is adopted. It is worth noticing that the construction of these indicators
is facilitated since the characteristics of the campaigns are rather similar.
Information on instruments for policies (population density, size of country,
women employment rate, production of milk and pig meat, the use of fertilizers)
are also obtained from the Eurostat statistics (Eurostat, 2010).
Since almost all countries implemented some policies to increase the public aware-
ness of antibiotic use from 2000, and in order to have a satisfactory control group, we
excluded Iceland from the nal dataset. Iceland adopted a campaign at the begin-
ning of the period considered (1997 and 1998). The nal dataset is an unbalanced
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panel dataset with 153 observations for Model 1 and 122 observations for Model
2. Since information on instrumental variables for policies is not available for all
countries or years, the number of observations in Model 2 is lower. Estimations are
performed by means of the statistical software STATA (version 11.1).
5 Results
For the estimation of Equation (1) with panel data, the literature proposes several
approaches: the pooled ordinary least-squares model (OLS), the random e¤ects
model (RE) and the xed e¤ects model (FE). As explained in section 3, we are
interested in applying a DD methodology. Consequently, we perform some tests to
choose the most appropriate estimator among those mentioned above.
Our initial tests indicate that the OLS model can be rejected in favour of the xed
e¤ects model (FE).3 The Breusch and Pagan Lagrangian multiplier test indicates
that there are other e¤ects than those captured by the exogenous variables in OLS
regressions. The F test that constant terms are homogeneous across regions and
time periods is also rejected. Moreover, the Hausman test suggests that the FE
approach should be preferred to the random e¤ects approach. For this reason we use
a DD estimator where the individual e¤ects are considered as xed. The parameter
estimates reported in Table 3 (Model 1) are those of the FE model. Table 3 also
reports the results of the two-stage least squares regression (Model 2) to correct for
endogeneity.
As explained in section 3, all regressions include country xed e¤ects and year
dummy variables. The results are stable and no structural di¤erences is observed
across the two models. Time dummies do not show any signicant increase in the
use of outpatient antibiotics per capita over time. In both models some coe¢ cients
are statistically signicant and carry the expected sign. The relatively low number
of statistically signicant coe¢ cients of socioeconomic variables could be explained,
as suggested by Cameron and Trivedi (2005), by the low within variation of these
3Preliminary OLS regressions show an R2 adjusted of 0.59. The goodness of t slighly increases
with the inclusion of temporal dummy variables. The F test is 24.58 (12.51 with time dummies).
This suggests that overall regressors have a signicant impact on the dependent variable. Moreover,
the mean Variance Ination Factor is lower than 3. Finally, the Shapiro-Wilk test as well as the
Jarque-Bera test for normality of errors cannot be rejected using the conventional 95% level of
signicance.
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variables. The number of signicant coe¢ cients increases in the two-stage least
squares model. Although this is worth of notice, we remind the reader that our
main goal is to estimate the coe¢ cient of the policy dummy variable using a DD
approach.
5.1 E¤ects of policies
The e¤ects of antibiotic policies on outpatient antibiotic consumption are reported
in Table 3. As explained in section 3, the control group consists of all the countries
that did not go through a public campaign to improve antibiotic use during 1997-
2007. Thus, when we study the e¤ects of public campaigns, the controls are the
countries that never adopted a campaign.
The variable POLICY1 is a dummy variable equal to 1 in the year of adoption
of the campaign and 0 afterwards for the treated countries only. Its estimated
coe¢ cient captures the average e¤ect of the policy. In line with our expectations,
policy coe¢ cients are signicant in both models. The dummy variable shows a
negative sign, which suggests that the implementation of public campaigns leads to
a reduction in the use of antibiotics. One could speculate that individuals informed
about the social implications of antibiotic use are more likely to use antibiotics
carefully.4
Using the estimated coe¢ cients of POLICY1 in Model 1 and Model 2, we observe
that the implementation of a public campaign may reduce antibiotic consumption
by 1.4 to 3.7 dened daily doses per 1,000 inhabitants. This roughly represents
an impact between 7.2% and 18.5% on the mean level of antibiotic use in Europe
between 1997 and 2007.
Our results cannot be easily compared with earlier ndings in the literature.
There is no comparable study we are aware of on the association between outpatient
antibiotic use and public campaigns. The few papers that have investigated the
correlation between antibiotic policies and antibiotic use either focus on specic
countries or do not use quantitative methods, as presented in section 2.
4The results above are conrmed if we include the dummy variable POLICY2 which takes the
value equal to 1 in the years of campaign adoption as well as in the years post-campaign. This
indicator was suggested by the logic that policies need to take some time to show their e¤ects.
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5.2 Other e¤ects of covariates
The coe¢ cient on physicians density deserves some comments since it is positive and
signicant in Model 2. An increase in physicians density by 0.1% increases antibiotic
consumption by 3.13 DID. The results might put forward some evidence of supply-
induced demand. However, the assumption of a positive relationship between the
amount of prescriptions and the number of doctors per capita does not necessarily
follow. It is known that countries with a greater number of doctors per inhabitant
use more antibiotics than countries with a smaller number of doctors per inhabitant
(Molstad et al., 2002), and that doctors who spend more time with their patients
prescribe fewer antibiotics (Bjerrum et al., 1999).
Although physicians are more informed than patients about drug resistance and
are ethically constrained to avoid unnecessary antibiotics, they may overprescribe
antimicrobials either to meet patients expectations or because they fear misdiagnos-
ing bacterial infections (Cizman, 2003). Patients usually regard antibiotics as a valid
alternative to anti-inammatory drugs for colds or u. They also su¤er from poor
information in relation to physicians and look for evidence of physicians quality.
The physicians willingness to prescribe antibiotics may then appear as a mark of
quality (Das and Sohnesen, 2006). Patients may fancy immediate treatment and the
physician must decide between prescribing or persuading the patient that a delay is
appropriate.
We did not nd any signicant e¤ect of changes in the average national income.
Nevertheless, the coe¢ cient of income is positive in both regressions. Positive income
e¤ects for antimicrobials are observed by Baye et al. (1997) using US data, Filippini
et al. (2009a) using aggregated Swiss data at small area level, and in a previous
study on European country data with a shorter time period, i.e. 2000-2005, than
ours (Masiero et al., 2010). Conversely, negative income e¤ects are found by Filippini
et al. (2006) using Swiss data at cantonal level. One possible explanation for the
relatively low value of the coe¢ cient of income is that the increasing concern on
the e¤ects of bacterial resistance from the 1990s may have reduced income elasticity
of outpatient antibiotic expenditure over time. Another explanation is that high-
income countries are more likely to substitute away antibiotics for other treatments,
ceteris paribus.
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As expected, antibiotic price has a negative impact on consumption, although
this is not signicant. Generally, antibiotics are perceived as necessary in the case of
presumed bacterial infections. Furthermore, antibiotics are purchased under doctors
prescription and the share of price bore directly by the patient is usually very low.
This may imply that individuals are not very responsive to changes in antibiotic
prices, although price demand elasticities may also vary according to the type of
antibiotic therapy, e.g. newer and more expensive antibiotics are more price elastic
than traditional ones (Filippini et al., 2009b).
The coe¢ cients of mortality rate for infectious diseases are not signicant. As for
demographic covariates, we only observe a signicant association between the pro-
portion of individuals aged 65-79 and increasing levels of antimicrobial consumption.
This result seems to support the hypothesis that increasing prevalence of chronic
health problems as people grow older may determine an increase in the utilization
of health care goods and services, including drugs. Di Matteo and Grootendorst
(2002) also observe a slightly signicant increase in drug expenditure in the popula-
tion between 64 and 74, although the evidence is not conrmed by the more recent
study by Di Matteo (2005).
6 Conclusion
Several studies show that a decrease in the use of antibiotics may reduce levels of
bacterial resistance. During the last decade, many European countries undertook
public health programs to optimize antibiotic use in the community. Nevertheless,
the e¤ectiveness of policies for a rationale use of antibiotics is still unclear. In
particular, the inuence of public campaigns on antimicrobial usage, and therefore
on bacterial resistance, has not been assessed accurately (Huttner et al., 2010).
In this paper, we estimate the impact of antibiotic policies in Europe by means
of a di¤erences-in-di¤erences methodology. The approach allowed us to identify the
e¤ect of campaigns on antibiotic use by relating di¤erential changes in antibiotic
use across countries and over time to changes in the relevant policy variables. The
key identication assumption in our analysis is that national policies are likely to
a¤ect antibiotic consumption more in countries where levels of bacterial resistance
are higher as compared to other countries.
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The results provide some evidence that the use of public campaigns represents
an e¤ective strategy to reduce the overuse of outpatient antibiotics. Countries that
adopt public campaigns succeed in terms of reducing their levels of antibiotic use
over time. Further research is necessary to assess the impact of policy interventions
on the levels of bacterial resistance through the reduction of antibiotic consumption.
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Figure 1: Antibiotic consumption and levels of bacterial resistance in PNSP (rate of
penicillin-non-susceptible Streptococcus pneumoniae isolates) in 20 European coun-
tries between 2000 and 2007. Data source: European Surveillance of Antimicrobial
Consumption (ESAC) and European Antimicrobial Resistance Surveillance System
(EARSS).
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Figure 2: Outpatient antibiotic use in DID (dened daily doses per 1000 inhabitants
per day) by country and year (2000-2007). Data source: European Surveillance of
Antimicrobial Consumption (ESAC).
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Description Variables Mean Std. dev. Min. Max.
Outpatient antibiotic DDDs per 1000 inhab. 19.87 5.83 9.75 34.73
consumption per day (DID)
Income per capita GDP in PPP/pop. (Y) 26802.27 10363.57 8898 71400
Antibiotic price Comparative price levels for 95.23 23.81 36.65 165.58
pharmaceutical products (P)
Demographic structure Pop. under 14/pop. (POP1) 17.78 2.36 13.90 25.70
of population Pop. 15-24/pop. (POP2) 13.29 1.83 10.20 17.50
Pop. 25-64/pop. (POP3) 53.84 1.94 47.90 58.1
Pop. 65-79/pop. (POP4) 11.55 1.55 8.2 15.20
Pop. over 80/pop. (POP5) 3.54 0.82 1.80 5.40
Density of doctors Nr./1000 inhab. (DPH) 3.15 0.61 1.90 4.90
Infections Mortality rate for 6.77 3.42 2.00 20.10
infectious diseases (INF)
Population density Population/km2 101.93 53.92 2.91 393.90
Country area km2 203068 170053 2586 551500
Animal production Tons of cows milk/1000 6300.63 7265.99 112.95 28723.91
Number of pigs/1000 10509.78 15469.91 73.72 81321
Use of fertilizers Tons/1000 919186 1115849 15852 4988800
Table 1: Variables notation and summary statistics Data sources: ESAC, OECD,
Eurostat, and European Observatory of Health Systems and Policies.
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Country Year
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Austria
Belgium      
Czech Republic
Germany        
Denmark
Spain  
Finland
Hungary
Ireland
Iceland  
Italy
Luxemburg    
The Netherlands
Poland
Portugal    
Sweden
Slovakia
United Kingdom
France      
Greece   
Norway 
Table 2: The implementation of national campaigns in Europe between 1997 and
2007 (years of campaign implementation are highlighted).
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Model 1 (Fixed e¤ects) Model 2 (2SLS)
Obs. 153 Obs. 122
Variables Coe¢ cients St. Err. p-value Coe¢ cients St. Err. p-value
Constant 13.38773 10.81521 0.231 -12.30656 15.41851 0.425
Y 0.000023 0.000064 0.730 0.000121 0.000118 0.305
INFt 1 -0.024336 0.131526 0.855 0.071602 0.143798 0.619
DPH 2.578951 1.729093 0.152 3.128074 1.356139 0.021
POP1 -0.162891 0.307134 0.602 0.211355 0.458741 0.645
POP2 -0.507961 0.327057 0.137 -0.076476 0.317848 0.810
POP4 1.804238 0.355211 0.000 2.198311 0.480476 0.000
POP5 -2.185347 1.738107 0.224 -1.936096 1.650253 0.241
P -0.051554 0.035081 0.158 -0.028272 0.043339 0.514
POLICY1 -1.437221 0.567456 0.020 -3.682141 1.502993 0.014
dt1 -0.477217 1.849433 0.799 0.280478 1.753773 0.873
dt2 -1.145775 1.768012 0.525 -0.163466 1.607206 0.919
dt3 -1.423682 1.604730 0.386 -0.443355 1.413800 0.754
dt4 -0.928832 1.452470 0.530 0.211679 1.181271 0.858
dt5 -1.399952 1.2144970 0.263 -0.157246 0.934441 0.866
dt6 -1.124569 0.919446 0.236 0.039486 0.724095 0.957
dt7 -1.764281 0.748660 0.029 -0.646103 0.553530 0.243
dt8 -0.783783 0.632413 0.230 - - -
dt9 -1.305654 0.478819 0.013 - - -
u 5.893451 - - 5.878605 - -
e 1.139026 - - 1.234114 - -
 0.963992 - - 0.957788 - -
Table 3: Parameter estimates for di¤erences-in-di¤erences models of antibiotic con-
sumption.
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